The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome
Open accessAbstract
Although some reports have found an association between increasing HLA disparity between donor and recipient and fewer relapses after allogeneic blood or marrow transplantation (BMT), this potential benefit has been offset by more graft-versus-host disease (GVHD) and nonrelapse mortality (NRM). However, the type of GVHD prophylaxis might influence the balance between GVHD toxicity and relapse. The present study analyzed the impact of greater HLA disparity on outcomes of a specific platform for nonmyeloablative (NMA), HLA-haploidentical transplantation. A retrospective analysis was performed of 185 patients with hematologic malignancies enrolled in 3 similar trials of NMA, related donor, haploidentical BMT incorporating high-dose posttransplantation cyclophosphamide for GVHD prophylaxis. No significant association was found between the number of HLA mismatches (HLA-A, -B, -Cw, and -DRB1 combined) and risk of acute grade II-IV GVHD (hazard ratio [HR] = 0.89; P = .68 for 3-4 vs fewer antigen mismatches). More mismatching also had no detrimental effect on event-free survival (on multivariate analysis, HR = 0.60, P = .03 for 3-4 vs fewer antigen mismatches and HR = 0.55, P = .03 for 3-4 vs fewer allele mismatches). Thus, greater HLA disparity does not appear to worsen overall outcome after NMA haploidentical BMT with high-dose posttransplantation cyclophosphamide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Cited by
Bashey, A., Zhang, X., Sizemore, C. A., Manion, K., Brown, S., Holland, H. K., Morris, L. E., & Solomon, S. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.3523 · Cited by 499
Self-citationWho is the best donor for a related HLA haplotype-mismatched transplant?
Wang, Y., Chang, Y.-J., Xu, L.-P., Liu, K.-Y., Liu, D.-H., Zhang, X.-H., Chen, H., Han, W., Chen, Y.-H., Wang, F.-R., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563130 · Cited by 344
Xu, L., Chen, H., Chen, J., Han, M., Huang, H., Lai, Y., Liu, D., Liu, Q., Liu, T., Jiang, M., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0564-x · Cited by 294
Fabricius, W. A., & Ramanathan, M. (2016) · Advances in Hematology · doi:10.1155/2016/5726132 · Cited by 46
Metadata
- Authors
- Kasamon, Y. L., Luznik, L., Leffell, M. S., Kowalski, J., Tsai, H.-L., Bolaños-Meade, J., Morris, L. E., Crilley, P. A., O'Donnell, P. V., Rossiter, N., Huff, C. A., Brodsky, R. A., Matsui, W. H., Swinnen, L. J., Borrello, I., Powell, J. D., Ambinder, R. F., Jones, R. J., & Fuchs, E. J.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 16
- Issue
- 4
- Pages
- 482-489
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2072290737
- Cited by
- 281
- References
- 1
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. https://app.cochat.ai/papers/10.1016/j.bbmt.2009.11.011
- The paper
- Kasamon, Y. L., Luznik, L., Leffell, M. S., Kowalski, J., Tsai, H.-L., Bolaños-Meade, J., Morris, L. E., Crilley, P. A., O'Donnell, P. V., Rossiter, N., Huff, C. A., Brodsky, R. A., Matsui, W. H., Swinnen, L. J., Borrello, I., Powell, J. D., Ambinder, R. F., Jones, R. J., & Fuchs, E. J. (2010). Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2009.11.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
